HMOX1 and neoplasm: A study by Kang et al. (2015) in an MCF-7 xenograft model (n = 5, NOG mice co-injected with human PBMCs) found oral STB-HO (35 and 70 mg/kg) significantly reduced final tumor volume and mass (p < 0.01) over 12 weeks (Kang et al., 2015).